Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The U.S. Food and Drug Administration recently approved a four-factor prothrombin complex concentrate (4-PCC) for warfarin reversal. The literature supporting its use over three-factor prothrombin complex concentrate (3-PCC) is limited.
Objective: Our objective was to retrospectively compare the efficacy of 3-PCC to 4-PCC in reversing warfarin in patients who were actively bleeding.
Methods: We conducted a single-center, retrospective cohort analysis of adult patients who received 3-PCC or 4-PCC for international normalized ratio (INR) reversal. Our study excluded patients not actively bleeding and not on warfarin. The main outcome was the percentage of patients who achieved warfarin reversal defined as INR ≤ 1.3 at first INR check post factor administration. We recorded baseline data including PCC dose, location of bleed, pre- and posttreatment INR, and time to INR reversal.
Results: We included a total of 53 patients. Intracranial hemorrhage was the most common site of bleeding (26 [74.3%] in 3-PCC vs. 12 [66.7%] in 4-PCC). The mean dose of 3-PCC was 25.5 units/kg, compared to 27.9 units/kg of 4-PCC. The mean baseline INR was 2.3 in the 3-PCC group and 3 in the 4-PCC group (p = 0.03), and the first posttreatment INRs were 1.4 and 1.2, respectively (p < 0.01). Warfarin reversal was achieved in 15 (42.9%) patients who received 3-PCC and 15 (83.3%) patients who received 4-PCC (p < 0.01). Faster time to INR reversal was noted in the 4-PCC group vs. the 3-PCC group (3.7 vs. 5 h, p = 0.48).
Conclusion: A higher percentage of patients achieved warfarin reversal with 4-PCC compared to 3-PCC treatment. A prospective randomized control trial is necessary to confirm our results.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jemermed.2015.07.024 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fixed-Dose Four-Factor Prothrombin Complex Concentrate for Reversal of Anticoagulation: Evaluation of Efficacy, Safety, and Cost Savings.
J Hematol
August 2025
Versiti Blood Center of Wisconsin, Greenfield, WI 53220, USA.
Background: Four-factor prothrombin complex concentrate (4F-PCC) is used for warfarin reversal and off-label management of bleeding in patients taking direct oral anticoagulants (DOACs). Dosing strategies that optimize hemostatic efficacy and cost, such as fixed dosing of 4F-PCC, are still under evaluation. The objective of this study was to retrospectively evaluate the efficacy, safety, and cost savings of fixed-dosing of 4F-PCC (1,500 IU for warfarin, 2,000 IU for DOACs).
View Article and Find Full Text PDFWarfarin-Induced Pulmonary Hemorrhage: A Rare and Life-Threatening Complication in the Resource-Limited Setting of Gaza.
Case Rep Pulmonol
August 2025
Department of Internal Medicine, European Gaza Hospital, Khan Yunis, Gaza Strip, State of Palestine.
Warfarin is widely prescribed for the prevention of thromboembolic events but carries a well-known risk of bleeding complications. While gastrointestinal and intracranial hemorrhages remain among the more frequent sites, pulmonary hemorrhage is an exceedingly rare case presentation and can be particularly catastrophic. We report the case of a 57-year-old male in Gaza with an extensive medical history of past hospitalization, who presented with severe ecchymosis, with his condition progressing to life-threatening pulmonary hemorrhage.
View Article and Find Full Text PDFInhibitory effects of Δ8-tetrahydrocannabinol on major hepatic cytochrome P450 enzymes and implications for drug disposition.
Drug Metab Dispos
July 2025
Division of Molecular Biosciences, Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York. Electronic address:
The increased use of cannabis in many parts of the United States and other countries has led to a need for a more comprehensive understanding of cannabis constituents and their potential for drug-drug interactions. Δ8-Tetrahydrocannabinol (Δ8-THC) is a psychoactive cannabinoid that is found at low concentrations in cannabis but is growing in popularity, especially where the use of Δ9-THC is restricted. Although certain cannabinoids including cannabidiol (CBD) are known to inhibit several metabolizing enzymes including many in the cytochrome P450 family, the effects of Δ8-THC remain poorly characterized.
View Article and Find Full Text PDFReversal of antithrombotic medications in patients with traumatic brain injury: What you need to know.
J Trauma Acute Care Surg
August 2025
From the Department of Surgery (E.P.), University of Minnesota; and North Memorial Health Robbinsdale Hospital (N.D., M.A.W.), Minneapolis, Minnesota.
Abstract: Traumatic brain injury (TBI) is a major public health problem and patients with TBI are frequently encountered by trauma surgeons. When TBI occurs in patients who are also taking antithrombotic medications, the risks and complications are increased. Antithrombotic medications can be classified as antiplatelet agents or anticoagulants.
View Article and Find Full Text PDFTiming of Anticoagulation Resumption in a Patient With Mechanical Heart Valves and Spontaneous Subdural Hematomas: A Case Report.
Cureus
June 2025
Cardiothoracic Surgery, University of South Florida, Tampa, USA.
Managing anticoagulation in patients with mechanical heart valves who develop a spontaneous intracranial hemorrhage is a challenging clinical scenario. Currently, there are no established guidelines on the optimal timing for the resumption of anticoagulation in this high-risk population. We report a case of a 61-year-old male with mechanical mitral and aortic valves on warfarin therapy for 9 years who presented with atraumatic subdural hematomas.
View Article and Find Full Text PDF